Excellent work, team!! 👏🏼 Opening up bronchoscopic lung volume reduction to a lot more folks than before. A true breakthrough #elvr #pulmonx #emphysema #respirology #bronchoscopy onlinelibrary.wiley.com/doi/10.1111/re…

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress healthcap.eu/jgwe

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma healthcap.eu/hzq9

HealthCap´s market report for Q2 2022 healthcap.eu/wp-content/upl…

Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3 healthcap.eu/ocau

CERAMENT®G showing outstanding long-term results bit.ly/3BnVzbm

Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market healthcap.eu/4m0u

InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth healthcap.eu/rgch

Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study healthcap.eu/ykv5

Karl Hedin frias i hovrätten. "Genom att överklaga tingsrättsdomen visade åklagaren att han tycker att han kan ta samhällets resurser i anspråk för något som bara verkar vara en önskan att skada mig", säger han till Fokus. fokus.se/aktuellt/karl-…

BONESUPPORT’S CERAMENT®G USED IN FIRST U.S. PATIENT CASES bit.ly/3TzaF4u

Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen healthcap.eu/t21w

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 healthcap.eu/k36j

Oncopeptides’ Pepaxti has been granted marketing authorization in the UK healthcap.eu/eyn9

Dear friends of HealthCap. We will suspend our Twitter. Communications will be through our website healthcap.eu and Linked-In linkedin.com/company/health…. Please follow us there.

lnkd.in/duDy4Sy6 lnkd.in/dWkp_8Fr

lnkd.in/djZfQ5Mi

In below podcast our colleague Mikaela Odlander, along with Edward Kliphuis Sofinnova Ventures, are discussing the potential with digital therapeutics but also the challenges entering the US market. #digitalhealth bblsa.com/investing-and-…

100% LIMB SALVAGE RATE IN COMPLEX DIABETIC FOOT CASES WITH CERAMENT® G/V – STUDY FROM KING’S COLLEGE HOSPITAL, LONDON bit.ly/3NX8k31

STRONG LONG-TERM RESULTS WITH CERAMENT®G FOR SEVERE OPEN FRACTURES – STUDY FROM MANCHESTER UNIVERSITY HOSPITAL bit.ly/3Oycq26